LTFS
GRCE

Ladenburg Thalmann Financial Services’s Grace Therapeutics GRCE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8
Closed -$1K – 4854
2016
Q1 		$1K Hold
8
– – ﹤0.01% 4571
2015
Q4 		$1K Hold
8
– – ﹤0.01% 4558
2015
Q3 		$1K Hold
8
– – ﹤0.01% 4470
2015
Q2 		$1K Hold
8
– – ﹤0.01% 4540
2015
Q1 		$2K Hold
8
– – ﹤0.01% 4312
2014
Q4 		$2K Hold
8
– – ﹤0.01% 4087
2014
Q3 		$3K Hold
8
– – ﹤0.01% 3591
2014
Q2 		$4K Sell
8
-9
-53% -$4.3K ﹤0.01% 3475
2014
Q1 		$9K Buy
+17
New +$10.4K ﹤0.01% 3027

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ladenburg Thalmann Financial Services's GRCE Position: Q2 2016 in Review

Ladenburg Thalmann Financial Services sold out of Grace Therapeutics (GRCE) in Q2 2016, closing a stake of 8 shares — an estimated $1K sold.

Ladenburg Thalmann Financial Services first reported a position in GRCE in Q1 2014 and held it in 9 quarters. The position peaked at $9K in Q1 2014. 8 funds tracked by Wall St. Rank hold GRCE as of Q2 2016.

  • Ladenburg Thalmann Financial Services reported no remaining Grace Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 8 Grace Therapeutics shares in Q2 2016, an estimated $1K.
  • Ladenburg Thalmann Financial Services first reported a position in Grace Therapeutics in Q1 2014 and held it in 9 quarters.
  • Ladenburg Thalmann Financial Services's Grace Therapeutics position peaked at $9K in Q1 2014.
  • 8 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2016.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2016, filed 15 Aug 2016.